首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccl19 |
| Uniprot No | Q99731 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-98aa |
| 氨基酸序列 | GTNDAEDCCLSVTQKPIPGYIVRNFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS |
| 预测分子量 | 35.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Production and functional characterization of recombinant CCL19 chemokine" by Smith A et al.**
- 摘要：该研究描述了大肠杆菌中重组CCL19蛋白的表达和纯化方法，验证了其体外诱导T细胞迁移的趋化活性，证实了重组蛋白的生物活性与天然形式一致。
2. **"CCL19 promotes dendritic cell migration and primes adaptive immunity in a murine model" by Li Y et al.**
- 摘要：通过重组CCL19蛋白处理小鼠模型，发现其增强树突状细胞向淋巴结的迁移能力，并显著提高抗原呈递效率，提示其在疫苗佐剂开发中的潜在应用。
3. **"Recombinant CCL19 suppresses tumor growth via enhancing T cell infiltration in melanoma" by Chen H et al.**
- 摘要：研究证明局部注射重组CCL19可通过募集CCR7+ T细胞至肿瘤微环境抑制黑色素瘤生长，为肿瘤免疫治疗提供了新策略。
4. **"Structural and functional analysis of glycosylated versus non-glycosylated CCL19" by Müller S et al.**
- 摘要：比较哺乳动物细胞(糖基化)与原核系统(非糖基化)表达的重组CCL19.发现糖基化修饰影响其蛋白稳定性但非趋化功能，为不同应用场景下的生产系统选择提供依据。
**Background of CCL19 Recombinant Protein**
CCL19 (C-C motif chemokine ligand 19) is a small secreted protein belonging to the CC chemokine family, which plays a critical role in immune cell trafficking and lymphoid tissue organization. It is constitutively expressed in secondary lymphoid organs, such as lymph nodes and the spleen, primarily by stromal cells and dendritic cells. CCL19 binds to the G protein-coupled receptor CCR7. guiding the migration of CCR7-expressing immune cells, including naïve T cells, dendritic cells, and regulatory T cells, to specific regions within lymphoid tissues. This process is essential for adaptive immune responses, including antigen presentation, T-cell activation, and immune tolerance.
Recombinant CCL19 is produced using biotechnological methods, often via expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. Unlike its closely related homolog CCL21. CCL19 lacks a C-terminal heparin-binding domain, resulting in distinct diffusion properties and localized signaling. Studies highlight its involvement in both physiological and pathological contexts, such as autoimmune diseases, cancer metastasis (via CCR7-mediated tumor cell migration), and chronic inflammation.
Research applications of recombinant CCL19 include *in vitro* and *in vivo* models to study immune cell behavior, lymphoid tissue development, and therapeutic interventions. Its potential as a therapeutic agent is being explored, particularly in enhancing vaccine efficacy or modulating immune cell recruitment in cancer immunotherapy. However, challenges remain in optimizing its stability and delivery *in vivo*. Overall, CCL19 recombinant protein serves as a vital tool for dissecting immune regulation mechanisms and developing targeted therapies.
×
